Evolving lipid-based delivery systems in the management of neoplastic disease

Oncology Reviews

Volumn 3, Issue 2, 2009, Pages 113-124

  Shapira, Iuliana ^a   Budman, Daniel R ^a   Bradley, Thomas ^a   Gralla, Richard ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Drug delivery; Liposomes; Nanoliposomes; Nanoparticles; Sphingosomes; Targeted therapy

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANIONIC LIPOSOME; CATIONIC LIPOSOME; CHOLESTEROL; CISPLATIN; CYTARABINE; DAUNORUBICIN; DILAUROYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; GEMCITABINE; IMMUNOLIPOSOME; IRINOTECAN; LIPOSOME; LURTOTECAN; MACROGOL; METHOXYMACROGOL DISTEAROYLGLYCEROPHOSPHOETANOLAMINE; NANOSOME; NAVELBINE; OPTISOME; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; RUBITECAN; SPHINGOMYELIN; SPHINGOSOME; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CARDIOMYOPATHY; CHEMICAL COMPOSITION; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED DRUG RELEASE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG STABILITY; ENCAPSULATION; ENDOMETRIUM CANCER; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; KAPOSI SARCOMA; LEUKEMIA REMISSION; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; MICELLE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PARTICLE SIZE; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 67650691925     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-009-0009-4     Document Type: Review

References (109)

1. JD Floyd DT Nguyen RL Lobins 2005 Cardiotoxicity of cancer therapy J Clin Oncol 23 7685 7696 (Pubitemid 46291833)
2. K Cho X Wang S Nie 2008 Therapeutic nanoparticles for drug delivery in cancer Clin Cancer Res 14 1310 1316
3. RR Patil SA Guhagarkar PV Devarajan 2008 Engineered nanocarriers of doxorubicin: a current update Crit Rev Ther Drug Carrier Syst 25 1 61
4. DR Budman 2000 Capecitabine Invest New Drugs 18 355 363 (Pubitemid 30778064)
5. P Wentworth A Datta D Blakey 1996 Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing Proc Natl Acad Sci USA 93 799 803
6. V Wagner A Dullaart AK Bock 2006 The emerging nanomedicine landscape Nat Biotechnol 24 1211 1217 (Pubitemid 44564760)
7. H Hashizume P Baluk S Morikawa 2000 Openings between defective endothelial cells explain tumor vessel leakiness Am J Pathol 156 1363 1380 (Pubitemid 30660013)
8. G Sessa G Weissmann 1968 Phospholipid spherules (liposomes) as a model for biological membranes J Lipid Res 9 310 318
9. DC Drummond CO Noble ME Hayes 2008 Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development J Pharm Sci 97 4696 4740
10. TM Allen C Hansen 1991 Pharmacokinetics of stealth versus conventional liposomes: effect of dose Biochim Biophys Acta 1068 133 141
11. B Banerji CR Alving 1990 Antibodies to liposomal phosphatidylserine and phosphatidic acid Biochem Cell Biol 68 96 101 (Pubitemid 20259647)
12. N van Rooijen 2008 Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages J Drug Target 16 529 534
13. HJ Lim D Masin TD Madden 1997 Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone J Pharmacol Exp Ther 281 566 573 (Pubitemid 27203116)
14. A Saupe KC Gordon T Rades 2006 Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy Int J Pharm 314 56 62
15. A Gabizon D Goren R Cohen 1998 Development of liposomal anthracyclines: from basics to clinical applications J Control Release 53 275 279 (Pubitemid 28218710)
16. T Lammers WE Hennink G Storm 2008 Tumour-targeted nanomedicines: principles and practice Br J Cancer 99 392 397
17. A Cabanes D Tzemach D Goren 1998 Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model Clin Cancer Res 4 499 505 (Pubitemid 28122769)
18. D Papahadjopoulos TM Allen A Gabizon 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci USA 88 11460 11464 (Pubitemid 21916061)
19. B Uziely S Jeffers R Isacson 1995 Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J Clin Oncol 13 1777 1785
20. PF Escobar M Markman K Zanotti 2003 Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer J Cancer Res Clin Oncol 129 651 654 (Pubitemid 37452631)
21. JA O'Shaughnessy 2003 Pegylated liposomal doxorubicin in the treatment of breast cancer Clin Breast Cancer 4 318 328 (Pubitemid 38139586)
22. KM Skubitz 2003 Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma Cancer Invest 21 167 176 (Pubitemid 36532162)
23. V Waldmann 2003 Liposomal doxorubicin in the treatment of metastasized angiosarcoma Br J Dermatol 148 606 (Pubitemid 36461357)
24. M Harrison D Tomlinson S Stewart 1995 Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma J Clin Oncol 13 914 920
25. E Winquist DS Ernst D Jonker 2003 Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract Eur J Cancer 39 1866 1871 (Pubitemid 37311182)
26. RZ Orlowski A Nagler P Sonneveld 2007 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 3892 3901 (Pubitemid 47477266)
27. E Rosenthal I Poizot-Martin T Saint-Marc 2002 Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma Am J Clin Oncol 25 57 59 (Pubitemid 34131030)
28. R Latagliata M Breccia P Fazi 2008 Liposomal daunorubicin versus standard daunorubicin: long-term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia Br J Haematol 143 681 689
29. X Yao K Panichpisal N Kurtzman 2007 Cisplatin nephrotoxicity: a review Am J Med Sci 334 115 124 (Pubitemid 47262919)
30. ES Kim C Lu FR Khuri 2001 A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer Lung Cancer 34 427 432 (Pubitemid 33041478)
31. KN Burger RW Staffhorst HC de Vijlder 2002 Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity Nat Med 8 81 84 (Pubitemid 34101733)
32. Q Ye J Asherman M Stevenson 2000 DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs J Control Release 64 155 166 (Pubitemid 30035316)
33. V Saroglou S Hatziantoniou M Smyrniotakis 2006 Synthesis, liposomal formulation and thermal effects on phospholipid bilayers of leuprolide J Pept Sci 12 43 50 (Pubitemid 43033697)
34. S Phuphanich B Maria R Braeckman 2007 A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study J Neurooncol 81 201 208 (Pubitemid 44963980)
35. MJ Glantz S LaFollette KA Jaeckle 1999 Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis J Clin Oncol 17 3110 3116 (Pubitemid 29470639)
36. MJ Glantz KA Jaeckle MC Chamberlain 1999 A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors Clin Cancer Res 5 3394 3402
37. S Sengupta D Eavarone I Capila 2005 Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 436 568 572 (Pubitemid 41112931)
38. L Boehlke JN Winter 2006 Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug Expert Opin Biol Ther 6 409 415
39. JK Horton PJ Houghton JA Houghton 1988 Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts Biochem Pharmacol 37 3995 4000 (Pubitemid 18254026)
40. LD Mayer D Masin R Nayar 1995 Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours Br J Cancer 71 482 488
41. DV Jackson Jr JB Craig CL Spurr 1990 Vincristine infusion with CHOP-CCNU in diffuse large-cell lymphoma Cancer Invest 8 7 12 (Pubitemid 20295659)
42. JD Bellone 1981 Treatment of vincristine extravasation Jama 245 343 (Pubitemid 11212999)
43. AH Sarris F Hagemeister J Romaguera 2000 Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial Ann Oncol 11 69 72 (Pubitemid 30084582)
44. AM Hillery 2000 New liposomal formulation of vincristine for non-Hodgkin's lymphoma Pharm Sci Technol Today 3 79 80 (Pubitemid 30176031)
45. DA Thomas AH Sarris J Cortes 2006 Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia Cancer 106 120 127 (Pubitemid 43032556)
46. Trial initiated for liposomal vincristine in relapsed/refractory acute lymphoblastic leukemia (2006) Oncology (Williston Park) 20:1292
47. SG Arbuck CH Takimoto 1998 An overview of topoisomerase I-targeting agents Semin Hematol 35 3 12
48. CH Takimoto J Wright SG Arbuck 1998 Clinical applications of the camptothecins Biochim Biophys Acta 1400 107 119 (Pubitemid 28475098)
49. T Minko PV Paranjpe B Qiu 2002 Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells Cancer Chemother Pharmacol 50 143 150 (Pubitemid 34969511)
50. VM Santana WL Furman CA Billups 2005 Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach J Clin Oncol 23 4039 4047 (Pubitemid 46211308)
51. F Muggia R Kosloff L Liebes 2006 Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan Oncologist 11 529 531 author reply 531-2 (Pubitemid 43788279)
52. TG Burke AK Mishra MC Wani 1993 Lipid bilayer partitioning and stability of camptothecin drugs Biochemistry 32 5352 5364 (Pubitemid 23167976)
53. P Tardi E Choice D Masin 2000 Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models Cancer Res 60 3389 3393 (Pubitemid 30482152)
54. HR Hinz NJ Harris EA Natelson 1994 Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice Cancer Res 54 3096 3100
55. V Knight N Koshkina C Waldrep 2000 Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice Trans Am Clin Climatol Assoc 111 135 145
56. NV Koshkina BE Gilbert JC Waldrep 1999 Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice Cancer Chemother Pharmacol 44 187 192 (Pubitemid 29350173)
57. CF Verschraegen BE Gilbert E Loyer 2004 Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies Clin Cancer Res 10 2319 2326 (Pubitemid 38445689)
58. DF Kehrer O Soepenberg WJ Loos 2001 Modulation of camptothecin analogs in the treatment of cancer: a review Anticancer Drugs 12 89 105 (Pubitemid 32207358)
59. GG Dark AH Calvert R Grimshaw 2005 Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the National Cancer Institute of Canada clinical trials group J Clin Oncol 23 1859 1866 (Pubitemid 46211363)
60. FJ Giles MS Tallman G Garcia-Manero 2004 Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia Cancer 100 1449 1458 (Pubitemid 38366848)
61. F Duffaud M Borner P Chollet 2004 Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: an EORTC New Drug Development Group study Eur J Cancer 40 2748 2752 (Pubitemid 39574727)
62. Y Ando H Saka G Asai 1998 UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Ann Oncol 9 845 847 (Pubitemid 28440442)
63. P Bosma JR Chowdhury PH Jansen 1995 Genetic inheritance of Gilbert's syndrome Lancet 346 314 315
64. V Peikov S Ugwu M Parmar 2005 pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation Int J Pharm 299 92 99 (Pubitemid 40962410)
65. EH Kraut MN Fishman 2005 Final results of phase I study of liposome-encapsulated SN-38 (LE-SN-38): safety, pharmacogenomics, pharmacokinetics and tumor response Proc Am Soc Clinic Oncol 23 111
66. SA Johnson P Harper GN Hortobagyi 1996 Vinorelbine: an overview Cancer Treat Rev 22 127 142 (Pubitemid 26235725)
67. IV Zhigaltsev N Maurer QF Akhong 2005 Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention J Control Release 104 103 111 (Pubitemid 40615239)
68. NK Ibrahim V Valero Z Rahman 2001 Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation Cancer Invest 19 459 466 (Pubitemid 32619386)
69. F Carabante-Ocon M Cobo-Dols M Benavides-Orgaz 2005 Continuous-infusion vinorelbine for the treatment of advanced non-small cell lung cancer: a phase I/II study Clin Lung Cancer 7 121 126 (Pubitemid 43192128)
70. AH Sarris A Psyrri F Hagemeister 2000 Infusional vinorelbine in relapsed or refractory lymphomas Leuk Lymphoma 39 291 299 (Pubitemid 32162366)
71. DC Drummond CO Noble Z Guo 2009 Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine J Pharmacol Exp Ther 328 321 330
72. SC Semple R Leone J Wang 2005 Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity J Pharm Sci 94 1024 1038 (Pubitemid 40780769)
73. Imperiale SM TA 2008 Phase 1 study of the sphingomyelin/cholesterol liposome formulation of vinorelbine in subjects with advanced solid tumors, Hodgkin's disease, or non-Hodgkin's lymphoma Annals Oncol 19 v145
74. C Lonez M Vandenbranden JM Ruysschaert 2008 Cationic liposomal lipids: from gene carriers to cell signaling Prog Lipid Res 47 340 347
75. KK Ewert A Ahmad NF Bouxsein 2008 Non-viral gene delivery with cationic liposome-DNA complexes Methods Mol Biol 433 159 175
76. S Dabbas RR Kaushik S Dandamudi 2008 Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells Endothelium 15 189 201
77. S Sonoke T Ueda K Fujiwara 2008 Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes Cancer Res 68 8843 8851
78. M Christopeit G Lenz R Forstpointner 2008 Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma Chemotherapy 54 309 314
79. Lohr M HS 2008 12-month survival data of a phase II trial: first-line treatment of inoperable pancreatic adenocarcinoma with cationic lipid complexed paclitaxel nanoparticles (EndoTAG-1) plus gemcitabine compared to gemcitabine monotherapy Annals Oncol 19 viii2 viii3
80. P Sun M Zhong X Shi 2008 Anionic LPD complexes for gene delivery to macrophage: preparation, characterization and transfection in vitro J Drug Target 16 668 678
81. T Boulikas GP Stathopoulos N Volakakis 2005 Systemic Lipoplatin infusion results in preferential tumor uptake in human studies Anticancer Res 25 3031 3039
82. GP Stathopoulos T Boulikas M Vougiouka 2005 Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study Oncol Rep 13 589 595
83. S Bandak D Goren A Horowitz 1999 Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models Anticancer Drugs 10 911 920 (Pubitemid 30061363)
84. EM Rezler DR Khan R Tu 2007 Peptide-mediated targeting of liposomes to tumor cells Methods Mol Biol 386 269 298
85. T Asai K Shimizu M Kondo 2002 Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels FEBS Lett 520 167 170 (Pubitemid 34607294)
86. E Friedlander M Barok J Szollosi 2008 ErbB-directed immunotherapy: antibodies in current practice and promising new agents Immunol Lett 116 126 140
87. KM Laginha EH Moase N Yu 2008 Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer J Drug Target 16 605 610
88. Pan D, Turner JL, Wooley KL (2003) Folic acid-conjugated nanostructured materials designed for cancer cell targeting. Chem Commun (Camb) (19):2400-2401 (Pubitemid 37289679)
89. C Foged HM Nielsen 2008 Cell-penetrating peptides for drug delivery across membrane barriers Expert Opin Drug Deliv 5 105 117 (Pubitemid 351234112)
90. A Doi S Kawabata K Iida 2008 Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy J Neurooncol 87 287 294
91. C Mamot DC Drummond U Greiser 2003 Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells Cancer Res 63 3154 3161 (Pubitemid 36735867)
92. JW Park CC Benz FJ Martin 2004 Future directions of liposome- and immunoliposome-based cancer therapeutics Semin Oncol 31 196 205 (Pubitemid 40023249)
93. JW Park K Hong DB Kirpotin 2002 Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin Cancer Res 8 1172 1181 (Pubitemid 35177372)
94. UB Nielsen DB Kirpotin EM Pickering 2002 Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis Biochim Biophys Acta 1591 109 118 (Pubitemid 35232074)
95. M Zignani DC Drummond O Meyer 2000 In vitro characterization of a novel polymeric-based pH-sensitive liposome system Biochim Biophys Acta 1463 383 394 (Pubitemid 30081796)
96. C Fonseca JN Moreira CJ Ciudad 2005 Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells Eur J Pharm Biopharm 59 359 366 (Pubitemid 40127593)
97. Leite EA, Dos Santos Giuberti C, Wainstein AJ et al (2009) Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sci [Epub ahead of print]
98. TP Chelvi R Ralhan 1995 Designing of thermosensitive liposomes from natural lipids for multimodality cancer therapy Int J Hyperthermia 11 685 695
99. LH Lindner ME Eichhorn H Eibl 2004 Novel temperature-sensitive liposomes with prolonged circulation time Clin Cancer Res 10 2168 2178 (Pubitemid 38375579)
100. V Frenkel A Etherington M Greene 2006 Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure Acad Radiol 13 469 479
101. A Szewczyk L Wojtczak 2002 Mitochondria as a pharmacological target Pharmacol Rev 54 101 127 (Pubitemid 34211027)
102. N Dias C Bailly 2005 Drugs targeting mitochondrial functions to control tumor cell growth Biochem Pharmacol 70 1 12 (Pubitemid 40797865)
103. M Okamaoto T Ohsato K Nakada 2003 Ditercalinium chloride, a pro-anticancer drug, intimately associates with mammalian mitochondrial DNA and inhibits its replication Curr Genet 43 364 370 (Pubitemid 37021063)
104. GG D'Souza R Rammohan SM Cheng 2003 DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells J Control Release 92 189 197 (Pubitemid 37138687)
105. F Yuan M Leunig SK Huang 1994 Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res 54 3352 3356 (Pubitemid 24225946)
106. TD McKee P Grandi W Mok 2006 Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector Cancer Res 66 2509 2513
107. PA Netti DA Berk MA Swartz 2000 Role of extracellular matrix assembly in interstitial transport in solid tumors Cancer Res 60 2497 2503 (Pubitemid 30262444)
108. C Keil R Zeisig I Fichtner 2005 Effect of surface modified liposomes on the aggregation of platelets and tumor cells Thromb Haemost 94 404 411 (Pubitemid 41122496)
109. O Lyass A Hubert AA Gabizon 2001 Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies Clin Cancer Res 7 3040 3046 (Pubitemid 32963822)